Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Glick, I. D.
space
  arrow  Marder, S.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

UPDATES FROM THE ANNUAL SESSION

2000-2001 Series: Update Sessions from ACP-ASIM's 2000 Annual Session

Margaret Ring Gillock, Editor; David Cramer, MD, Co-Editor; and Paul T. Kefalides, MD, Co-Editor

Psychopharmacologic Treatment Strategies for Depression, Bipolar Disorder, and Schizophrenia

right arrow Ira D. Glick, MD; Trisha Suppes, MD, PhD; Charles DeBattista, MD; Rona J. Hu, MD; and Stephen Marder, MD

2 January 2001 | Volume 134 Issue 1 | Pages 47-60

Patients with serious psychiatric disorders are frequently treated by primary care physicians, who may have difficulty keeping up with recent advances in psychiatry. This paper presents an updated synopsis for three major psychiatric illnesses: major depression, bipolar disorder, and schizophrenia. Current definitions, updated diagnostic criteria, short- and long-term treatment strategies with algorithms, and special challenges for the clinician are discussed for each of these illnesses. On the basis of each illness's distinct characteristics, five treatment principles are emphasized: 1) Treatment strategies should be long-term and should emphasize adherence, 2) treatment choice should be empirical, 3) combinations of medications may be helpful, 4) a combination of psychosocial and pharmacologic treatments may be more useful than either alone, and 5) the family or "significant others" as well as a consumer organization need to be involved. Some of the new directions in clinical research to refine these strategies and meet these challenges are also described.

Author and Article Information
space

From Stanford University School of Medicine, Stanford, California; University of Texas Southwestern Medical Center, Dallas, Texas; and University of California, Los Angeles, Los Angeles, California.

Grant Support: The authors have received financial and/or research funding support from various sources, including the following manufacturers of drugs that may be discussed in this manuscript: Abbott Laboratories, Zeneca, Eli Lilly, Pfizer, Janssen, Novartis, SmithKline Beecham, Parke-Davis, Glaxo Wellcome, Bristol-Meyers Squibb, Forrest Laboratories, Scios, Wyeth-Ayerst, Organon, and Pharmacia Upjohn.

Requests for Single Reprints: Ira D. Glick, MD, Stanford University School of Medicine, 401 Quarry Road, Suite 2122, Stanford, CA 94305-5723; e-mail, iraglick{at}stanford.edu.

Current Author Addresses: Dr. Glick: Stanford University School of Medicine, 401 Quarry Road, Suite 2122, Stanford, CA 94305-5723.

Dr. Suppes: Bipolar Disorder Clinic, Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9070.

Dr. DeBattista: Stanford University School of Medicine, 401 Quarry Road, Suite 2137, Stanford, CA 94305.

Dr. Hu: Stanford University School of Medicine, 401 Quarry Road, Suite 2114, Stanford, CA 94305.

Dr. Marder: West Los Angeles Veterans Affairs Medical Center, MIRECC 210A, 11301 Wilshire Boulevard, Los Angeles, CA 90072-1003.


Related articles in Annals:

Letters
New Psychopharmacologic Treatment Strategies
Peter E. Stokes
Annals 2001 135: 1008. [Full Text]  

Letters
New Psychopharmacologic Treatment Strategies
Ira D. Glick AND Charles DeBattista
Annals 2001 135: 1008. [Full Text]  



This article has been cited by other articles:


Home page
Health Aff (Millwood)Home page
N. E. Morden and L. P. Garrison Jr.
Implications of part d for mentally ill dual eligibles: a challenge for medicare.
Health Aff., March 1, 2006; 25(2): 491 - 500.
[Abstract] [Full Text] [PDF]


Home page
J Natl Cancer Inst MonogrHome page
M. Fisch
Treatment of Depression in Cancer
J Natl Cancer Inst Monographs, July 1, 2004; 2004(32): 105 - 111.
[Abstract] [Full Text] [PDF]


Home page
J Natl Cancer Inst MonogrHome page
D. B. Greenberg
Barriers to the Treatment of Depression in Cancer Patients
J Natl Cancer Inst Monographs, July 1, 2004; 2004(32): 127 - 135.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
S. B. Soumerai
Benefits And Risks Of Increasing Restrictions On Access To Costly Drugs In Medicaid
Health Aff., January 1, 2004; 23(1): 135 - 146.
[Abstract] [Full Text] [PDF]


Home page
Journal of the American Dental AssociationHome page
A. H. FRIEDLANDER, I. K. FRIEDLANDER, and S. R. MARDER
Bipolar I disorder: Psychopathology, medical management and dental implications
J Am Dent Assoc, September 1, 2002; 133(9): 1209 - 1217.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
P. E. Stokes
New Psychopharmacologic Treatment Strategies
Ann Intern Med, December 4, 2001; 135(11): 1008 - 1008.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
J. E. Calfee
Pharmaceutical Price Controls and Patient Welfare
Ann Intern Med, June 5, 2001; 134(11): 1060 - 1064.
[Abstract] [Full Text] [PDF]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2001 by the American College of Physicians.